Methods for reducing oxidative damage

Details Methods for reducing oxidative damage Methods for reducing oxidative damage

2005-01-21

2009-06-23

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S330000

Reexamination Certificate

active

07550439

ABSTRACT:
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pmis the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3aor 2ais the largest number that is less than or equal to pt+1, except that when a is 1, ptmay also be 1; and (f) at least one tyrosine or tryptophan amino acid.

REFERENCES:
patent: 5312899 (1994-05-01), Schiller
patent: 5602100 (1997-02-01), Brown et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5885958 (1999-03-01), Zadina
patent: 5993848 (1999-11-01), Suzuki et al.
patent: 5994372 (1999-11-01), Yaksh
patent: 6221355 (2001-04-01), Dowdy
patent: 6268398 (2001-07-01), Ghosh et al.
patent: 6503713 (2003-01-01), Rana
patent: 6703483 (2004-03-01), Schiller
patent: 6759520 (2004-07-01), Carr et al.
patent: 6900178 (2005-05-01), Oeltgen et al.
patent: 2004/0248808 (2004-12-01), Szeto et al.
patent: 2005/0096333 (2005-05-01), Dugar et al.
patent: 2005/0192215 (2005-09-01), Ghosh et al.
patent: 2007/0129306 (2007-06-01), Szeto et al.
patent: 2361364 (2000-09-01), None
patent: WO 9522557 (1995-08-01), None
patent: WO 00/55189 (2000-09-01), None
patent: WO 02/05748 (2002-01-01), None
Rudinger, J (1976). Peptide Hormones (Ed. J.A. Parson). University Park Press. baltomre pp. 1-7.
Bradley et al. ‘Limits of Cooperativeity in a Structurally Modula Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitution in Each Repeat.’ J. Mol. Biol. vol. 324, pp. 373-386. 2002.
Ngo et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox.” TheProtein Folding Problem and Tertiary structure Prediction. Ed. K. Merz and L. Le Grand. Birkhauser, Boston, Ma. 491-495.
Berendsen, Herman. “A Glimpse of the Holy Grail?” Science, vol. 282, pp. 642-643. Oct. 23, 1998.
File Medline on STN An No. 2005478947. Simmons, Zachary. “Management Strageies for Patients with Amyotrphoic Lateral Sclerosis from diagnosis Through Death.” The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Azzouz, Mimoun “Gene Therapy for ALS: Progress and Prospects” Biochemical et Biophysica Acta (2006), vol. 1762 pp. 1112-1127.
Pages et al. ‘Cystamine and Cysteamine Increase Brain Levels of BDNF in Huntington Disease VIA HSJ1b and Transglutaminase’ J. of Clin. Invest. vol. 116 No. 5, pp. 1410-1424. May 2006.
Margolis et al. ‘Diagonsis of Huntington Disease’ Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Korczyn et al. ‘Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease’ Drugs vol. 62, No. 5 pp. 775-786. 2002.
Sriram et al. ‘Experimental Allergic Encephalomyetlitis: A Misleading Model of Multiple Sclerosis’ Ann. Neurol. vol. 58, pp. 939-945. 2005.
Steinman et al. ‘How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multple Sclerosis’ Ann Neurol. vol. 60, pp. 12-21. 2006.
Citron, Martin. ‘Alzheimer's Disease: Treatment in Discovery and Development’ Nature Nuerosicence Supplment. vol. 5. pp. 1055-1057. Nov. 2002.
Patel et al. ‘Pharmacotherapy of Cognitive Impariment in Alzheimer's Disease: A Review’ J. Geriatr. Psychiatry Neruol. vol. 8 pp. 81-95. 1995.
Clapp III, et al. “Cardiovascular and Metabolic Responses to Two Receptor-Selective Opioid Agonists in Pregnant Sheep”, Am. J. Obstet. Gynecol., vol. 178, No. 2 (Feb. 1998) pp. 397-401.
Holsey, et al. “Cardiovascular Effects of a μ-Selective Opioid Agonist (Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in Fetal Sheep: Sites and Mechanisms of Action”, Am. J. Obstet. Gynecol., vol. 180, No. 5 (May 1999) pp. 1127-1130.
Kett, et al. “Baroreflex-Mediated Bradycardia but Not Tachycardia is Blunted Peripherally by Intravenous μ-opioid Agonists”, Am. J. Obstet. Gynecol., vol. 178, No. 5 (May 1998) pp. 950-955.
Neilan, et al. “Pharmacological Characterization of the Dermorphin Analog [Dmt1]DALDA, a Highly Potent and Selective μ-Opioid Peptide”, European Journal of Pharmacology, vol. 419, Issue 1 (2001) 15-23.
Omoniyi, et al. “A Peripheral Site of Action for the Attenuation of Baroreflex-Mediated Bradycardia by Intravenous μ-Opioid Agonists”, Journal of Cardiovascular Pharmacology™, vol. 35, No. 2 (2000) pp. 269-274.
Schiller, et al. “Dermorphin Analogucs Carrying an Increased Positive Net Charge in Their “Message” Domain Display Extremely High μ Opioid Receptor Selectivity”, Journal of Medicinal Chemistry, vol. 32, No. 3 (1989) pp. 698-703.
Schiller, et al. “Synthesis and In Vitro Opioid Activity Profiles of DALDA Analogues”, European Journal of Medicinal Chemistry, vol. 35, Issue 10 (Oct. 2000) pp. 895-901.
Shimoyama, et al. “Antinociceptive and Respiratory Effects of Intrathecal H-Tyr-D-Arg-Phe-Lys-NH2(DALDA) and [Dmt1] DALDA”, The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1 (Apr. 2001) pp. 364-371.
Szeto, et al. “In Vivo Disposition of Dermorphin Analog (DALDA) in Nonpregnant and Pregnant Sheep”, The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 1 (1998) pp. 61-65.
Szeto et al. “Respiratory Depression After Intravenous Administration of δ-Selective Opioid Peptide Analogs”, Peptides, vol. 20 (1999) pp. 101-105.
Szeto, et al. “Mu-Opioid Receptor Densensitization and Resensitization In Vivo”, International Narcotics Research Conference, Poster Abstracts, Monday (1999) Mon19, p. 5.
Szeto, et al. “In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists”, The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 1 (Jul. 2001) pp. 57-61.
Wu, et al. “Myocardial Protective Effect of Mu Opioid Agonists”, International Narcotics Research Conference, Poster Abstracts, Sunday (1999) Sun59, p. 15.
Zhao, et al. “Transcellular Transport of a Highly Polar 3+ Net Charge Opioid Tetrapeptide”, The Journal of Pharmacology and Experimental Therapeutics, vol. 304, (2003) pp. 425-432.
Zhao, et al. “Translocation of a 3+ Net Charge Tetrapeptide Across Plasma Membrane of Mammalian Cells”, World Congress of Pharmacology, Abstract, Published May 1, 2002.
Zhao, et al., “Profound Spinal Tolerance After Repeated Exposure to a Highly Selective μ-Opioid Peptide Agonist: Role of σ-Opioid Receptors”, vol. 302, (2002) pp. 188-196.
Wu, et al. “A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning”, Am. J. Physiol. Heart Circ. Physiol, 283: H-783-H791 (2002).
Broekemeier, et al., “Inhibition of the Mitochondrial Permeability Transition by Cyclosporin A during Long Time Frame Experiments: Relationship between Pore Opening and the Activity of Mitochondrial Phospholipases”, Biochemistry 1995, 34:16440-16449.
Zadina J. et al., “A Potent and Selective Endogeneous Agonist for the Mu-Opiate Receptor”, Nature, Nature Publishing Group, London, GB, vol. 386, Apr. 3, 1997, pp. 499-502, XP002072008.
Spetea, Mariana et al., “Interaction of agonist peptide (3H) Tyr-D-Ala-Phe-Phe-NH2 with mu-opioid receptor in rat brain and CHO-mu/1 cell line”, Peptides (New York), vol. 19, No. 6, 1998, pp. 1091-1098, XP002410285.
Dooley, C T et al., “Selective ligands for the mu, delta and kappa opioid

Affiliated with

Also associated with

Rating

Methods for reducing oxidative damage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for reducing oxidative damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing oxidative damage will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128591